Drug intelligence / Profile preview

CYB704

Development stage: Phase 3
Lead developer: Sandoz
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CYB704 is a proposed biosimilar to ocrelizumab (Ocrevus) being developed for the treatment of multiple sclerosis. It is a monoclonal antibody that works through antibody-dependent cell cytotoxicity (ADCC) and CD20-directed cytolytic effects. As a biosimilar to ocrelizumab, it targets CD20, a protein found on the surface of B cells, which are involved in the immune response that attacks the myelin sheath in multiple sclerosis.

Other names: Ocrelizumab Biosimilar

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on CYB704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYB704.

Explore the full profile